Strong clinical progress for LIB-01, robust financial position after oversubscribed rights issue, and expanded patent protection marked 2024. Phase 2a trial is fully funded, with results expected mid-2025, and LIB-01 shows promise for additional indications.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.